Neurizon Therapeutics Limited has released a press release.
Canine phase 2b cancer trial expands to New Zealand
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- MPL Manufacturing and Human Trials Update
- Following Extension of Survival, PAA Prepares Phase 3 Trial
- Prospectus
- Entitlement Options Offer
- Epichem Completes Final Loan Repayment
Later from Neurizon Therapeutics
- MND & COVID-19 Phase 1 Clinical Trials On-Track
- Demonstration batch of smaller size MPL tablets completed
- Shareholder Update - Progress and Strategy
- Epichem Awarded Contract Extension from DNDi
- Update on Manufacture of MPL & Tablets for Clinical Trials
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics